Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether DAC HYP, when compared to
placebo, is effective in reducing the rate of relapses between baseline and Week 52. The
secondary objectives are to determine whether DAC HYP is effective in reducing the number of
new gadolinium (Gd)-enhancing lesions, reducing the number of new or newly-enlarging T2
hyperintense lesions, reducing the proportion of participants with relapses, and improving
quality of life.